This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Seattle Genetics rare cancer drug sails through accelerated approval. Nat Biotechnol 29, 851–852 (2011). https://doi.org/10.1038/nbt1011-851
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1011-851
This article is cited by
-
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma
Oncogene (2014)
-
Fresh from the biotech pipeline 2011
Nature Biotechnology (2012)
-
State of the art in the treatment of Hodgkin lymphoma
Nature Reviews Clinical Oncology (2012)